Also from this source


Jul 25, 2018, 02:45 ET Indivior Announces H1 2018 Results...

You just read:

Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program

News provided by

Indivior PLC

Mar 29, 2018, 08:00 ET